Exelixis, Inc.

EXEL · Nasdaq · ·

비교

US$68.99-1.2%11월 13일 종가

2026년 10월 2일까지의 수치 (2026년 10월 29일 제출 10-Q 기준)

1W: -0.8%
1M: +9.8%
3M

Exelixis, Inc. (EXEL) 주식 — 좋은 사업일까? — InspectStocks

Exelixis, Inc.

EXEL · Nasdaq · ·

비교

US$68.99-1.2%11월 13일 종가

2026년 10월 2일까지의 수치 (2026년 10월 29일 제출 10-Q 기준)

1W: -0.8%
1M: +9.8%
3M

Just reported

Q3 FY2027 results

From Exelixis's results release of 2026년 10월 29일; its quarterly report has since been filed.

Revenue
Actual
US$658.7M
+10% y/y
+4.8% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$0.85
+23% y/y
+3.7% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$268.4M
+13% y/y
+8.1% q/q
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Exelixis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

큐레이션
Biotech
InspectStocks 제공 · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
주가, 1년
+26.8%
매출, 1년
+12.9%
+13
A 8B 4C 5D 1F 1

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 352 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

어떻게 돈을 버는가

Cabometyx sales38%
Cometriq sales0%
License revenue4%
Collaboration revenue4%

매출 비중은 year ended 2025-12-31 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

무엇을 파는가6

CABOMETYX (cabozantinib) tablets
A cancer medicine used alone for several cancers, including kidney, liver, thyroid and neuroendocrine cancers, and with nivolumab for some kidney cancers.
COMETRIQ (cabozantinib) capsules
A cabozantinib medicine for progressive, metastatic medullary thyroid cancer.
COTELLIC (cobimetinib)
A medicine used in combination treatments for certain forms of advanced melanoma; Genentech markets it under a collaboration with Exelixis.

3개 더 보기

MINNEBRO (esaxerenone)
A medicine for high blood pressure in Japan, licensed to Daiichi Sankyo.
Zanzalintinib
An experimental cancer medicine being tested alone and with other medicines. Exelixis has applied for U.S. approval of its use with atezolizumab for previously treated metastatic colorectal cancer.
XL309
An experimental medicine being tested in people with advanced solid tumors, alone and with a drug that blocks PARP, a protein involved in cell repair.

누가 사는가4

U.S. wholesalers and specialty pharmacies buy Cabometyx and Cometriq and may resell them to hospitals and other organizations that provide the medicines to patients.
Oncologists and other healthcare professionals prescribe and help patients obtain the medicines; Exelixis also provides reimbursement assistance and patient support.
Ipsen sells cabozantinib outside the United States and Japan and pays Exelixis royalties; Takeda sells it in Japan and pays Exelixis royalties.
Genentech markets Cotellic under a collaboration with Exelixis, and Daiichi Sankyo holds the license for Minnebro.

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1Cabometyx accounts for most of the company’s revenue, so sales depend substantially on physicians choosing it and patients continuing treatment.
2Ipsen handles cabozantinib commercialization outside the United States and Japan, and Takeda handles it in Japan; Exelixis does not control the amount or timing of their commercial investment.
3Exelixis relies on outside manufacturers to make its medicines and drug candidates, and on outside logistics providers to store and ship its U.S. commercial products.
4Sales depend on government and private health plans covering the medicines and reimbursing their cost; U.S. drug-pricing rules and other government measures can affect that coverage and reimbursement.

잘못될 수 있는 일

1Cabometyx faces competing cancer treatments, and lower physician or patient use could reduce the sales on which Exelixis relies.
2Generic and follow-on cabozantinib products could reduce Cabometyx revenue; the timing of their entry depends on regulatory decisions, patent disputes and settlement terms.
3Clinical trials or regulatory reviews may not lead to approval of new uses or new medicines, including zanzalintinib; even if approved, doctors and payers may not adopt or cover them.

전체 재무제표 보기 →

Exelixis, Inc. 소개

Exelixis’s main medicine is Cabometyx, a tablet used to treat several cancers, including kidney cancer; it is also used with Bristol Myers Squibb’s nivolumab for some patients. Exelixis sells Cabometyx and Cometriq in the United States, while Ipsen and Takeda sell cabozantinib in other countries and pay Exelixis royalties. The company also earns money from licensing and collaborating on other medicines, including Cotellic and Minnebro, and is developing cancer drug candidates such as zanzalintinib. The U.S. Food and Drug Administration is reviewing zanzalintinib with atezolizumab for previously treated colorectal cancer.

본사: Alameda, California, United States
설립: 1994
상장 시장: NASDAQ
회계연도 종료: 52- or 53-week year ending on the Friday closest to December 31

Exelixis, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.

Just reported

Q3 FY2027 results

From Exelixis's results release of 2026년 10월 29일; its quarterly report has since been filed.

Revenue
Actual
US$658.7M
+10% y/y
+4.8% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$0.85
+23% y/y
+3.7% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
US$268.4M
+13% y/y
+8.1% q/q
Guided
—
No guide given